GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Liabilities-to-Assets

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Liabilities-to-Assets : 0.74 (As of Nov. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Algernon Pharmaceuticals's Total Liabilities for the quarter that ended in Nov. 2023 was $2.14 Mil. Algernon Pharmaceuticals's Total Assets for the quarter that ended in Nov. 2023 was $2.88 Mil. Therefore, Algernon Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Nov. 2023 was 0.74.


Algernon Pharmaceuticals Liabilities-to-Assets Historical Data

The historical data trend for Algernon Pharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Liabilities-to-Assets Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only 0.07 0.05 0.10 0.31 0.65

Algernon Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.41 0.39 0.65 0.74

Competitive Comparison of Algernon Pharmaceuticals's Liabilities-to-Assets

For the Biotechnology subindustry, Algernon Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Liabilities-to-Assets falls into.



Algernon Pharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Algernon Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Liabilities-to-Assets (A: Aug. 2023 )=Total Liabilities/Total Assets
=2.018/3.112
=0.65

Algernon Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Nov. 2023 is calculated as

Liabilities-to-Assets (Q: Nov. 2023 )=Total Liabilities/Total Assets
=2.144/2.882
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals  (OTCPK:AGNPF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Algernon Pharmaceuticals Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Headlines

From GuruFocus

Algernon Pharmaceuticals Announces Launch of Rights Offering

By sperokesalga sperokesalga 03-21-2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

By Stock market mentor Stock market mentor 01-17-2023